Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
600 participants
OBSERVATIONAL
2016-10-01
2022-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It has been shown that excess aldosterone has other harmful effects in addition to hypertension, such as directly affecting the heart, blood vessels, kidneys, leading to increased cardiovascular morbidity and mortality. This is supported by studies showing reversal of these effects after treatment for PA.
The investigators aim to assess the long-term cardiovascular, and renal outcomes of patients with PA, compared to patients with essential hypertension.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Study Assessing Blood Pressure and Other Outcomes Post-treatment in Patients With Primary Aldosteronism
NCT03174847
Effects of Adrenal Artery Ablation and Adrenalectomy in Patients With Primary Aldosteronism
NCT04269928
Effects of Adrenal Artery Ablation and Spironolactone in Patients With Primary Aldosteronism
NCT04409431
Spatial Proteomics Profiles of Aldosterone-producing Adenoma and Unilateral Hyperplasia
NCT05927961
Postoperative Cardiovascular Index Change of Primary Aldosteronism
NCT00746070
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Surgery
Patients treated with surgery
Unilateral adrenalectomy in patients with unilateral disease
Unilateral adrenalectomy in patients with unilateral disease
Medications
Patients treated with mineralocorticoid antagonists or potassium sparing diuretics for primary aldosteronism
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Unilateral adrenalectomy in patients with unilateral disease
Unilateral adrenalectomy in patients with unilateral disease
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
14 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Singapore General Hospital
OTHER
Changi General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Troy Puar, MRCP
Role: PRINCIPAL_INVESTIGATOR
Changi General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Changi General Hospital
Singapore, , Singapore
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Puar TH, Loh LM, Loh WJ, Lim DST, Zhang M, Tan PT, Lee L, Swee DS, Khoo J, Tay D, Tan SY, Zhu L, Gani L, King TF, Kek PC, Foo RS. Outcomes in unilateral primary aldosteronism after surgical or medical therapy. Clin Endocrinol (Oxf). 2021 Feb;94(2):158-167. doi: 10.1111/cen.14351. Epub 2020 Oct 26.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PA_Outcome
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.